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Abstract
Background—There are few published studies on microtia-anotia frequency.
Methods—Using data from birth defects surveillance programs around the world, we conducted
a systematic review on the frequency of microtia-anotia to further explore the differences in
prevalence across countries. Ninety-two birth defects surveillance programs were evaluated with a
total of 8,917 cases of microtia-anotia. We computed the prevalence per 10,000 births for each
surveillance program for total cases of microtia-anotia (microtia types I to IV), microtia (types I to
III), and anotia (type IV). Prevalence ratios were calculated by large geographical areas, race/
ethnicity, and by surveillance methodologies.
Results—The overall prevalence were for microtia-anotia 2.06 (CI: 2.02–2.10), for microtia 1.55
(CI: 1.50–1.60), and for anotia 0.36 (CI: 0.34–0.38). Higher prevalence was observed in the
Americas, Northern Europe and Asia, among Hispanics and Asians, and among active
ascertainment and hospital-based surveillance programs.
Conclusions—We observed marked variation in the prevalence of microtia-anotia across
surveillance programs and within countries. These results must be interpreted cautiously as this
variability may be explained mainly by differences in surveillance methods. However, given the
magnitude of some of the differences, other factors may also be involved. This study contributes
to the knowledge on the prevalence of microtia-anotia by providing a critical analysis of the
existing data. In addition, it supports the need for a coding system that allows complete phenotype
characterization of microtia-anotia, including severity and laterality; as well as further studies on
the variation of its frequency related to race and ethnicity.
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Introduction
The external ear consists of the auricle, the external acoustic meatus and the tympanic
membrane. Microtia-anotia is a spectrum of congenital anomalies of the auricle ranging
from mild structural abnormalities to complete absence of the ear (anotia) (Carey et al.,
2006). A well-accepted classification of microtia-anotia was proposed by Marx (1926). In
the Marx classification, all of the features of a normal auricle are present in grade I, but the
pinna is smaller than normal. In grade II, some anatomical structures are still recognizable.
In the most common form, grade III (the peanut-shell type), only a rudiment of soft tissue is
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present. The extreme case where there is no external ear and auditory canal is called anotia
or microtia grade IV.
There is no consensus in the literature in relation to the terminology used for these external
ear malformations. Some authors prefer to use the term “microtia” (Alasti and Van Camp,
2009; Castilla and Orioli, 1986; Hunter et al., 2009; Suutarla et al., 2007) while others use
“microtia-anotia” or “microtia/anotia” (Canfield et al., 2009; Carey et al., 2006; Forrester
and Merz, 2005; Harris et al., 1996; Mastroiacovo et al., 1995; Shaw et al., 2004). Anotia,
from the dysmorphology-descriptive standpoint, is the most severe end of the microtia
spectrum. For the purpose of this paper we chose the term “microtia-anotia” because: (a) it
was a common term used in the literature to identify these two anomalies, (b) some of the
surveillance programs included in this study use this term to indicate that they do not
differentiated between microtia and anotia, while others only report anotia (but not microtia
types I to III). This term includes microtia types I to IV.
Microtia-anotia may occur as an isolated condition, or as part of a spectrum of anomalies or
a syndrome. It can occur unilaterally (79–93% of cases) or bilaterally; in unilateral cases the
right ear is more often affected (Suutarla et al., 2007). Individuals with unilateral microtia-
anotia usually have normal hearing in the unaffected ear (Eavey, 1995; Kelley and Scholes,
2007). Therefore, speech and language development are typically normal, although children
with microtia-anotia are at a greater risk of delayed language development and attention
deficit disorders (Eavey, 1995; Kelley and Scholes, 2007). Children with microtia-anotia
will have an associated anomaly or an identifiable syndrome pattern in 20–60% of cases
(Carey et al., 2006; Castilla and Orioli, 1986; Kaye et al., 1989; Mastroiacovo et al., 1995;
Shaw et al., 2004). The most common anomalies are facial cleft, facial asymmetry, renal
abnormalities, cardiac defects, microphthalmia, polydactyly, and vertebral anomalies (Harris
et al., 1996; Mastroiacovo et al., 1995).
The etiology of microtia-anotia is poorly understood. Much has been published regarding
surgical treatments and their outcomes (Chang et al., 2006; Habiballah and Bamousa, 2000;
Osorno, 2007; Tollefson, 2006), but few studies have focused on the environmental or
genetic causes of microtia-anotia. There is strong evidence supporting the importance of
environmental causes for microtia-anotia, such as altitude (Castilla et al., 1999; González-
Andrade et al., 2010) and gestational exposure to retinoids, alcohol, thalidomide and,
mycophenolate mofetil (Anderka et al., 2009; Carey et al., 2006; Klieger-Grossmann et al.,
2010). More recently, periconceptional intake of folic-acid-containing supplements was
associated with reduced risk of microtia-anotia among non-obese women (Ma et al., 2010).
Evidence for a genetic contribution to isolated microtia-anotia is based on: 1) higher
concordance in monozygotic twins than in dizygotic twins; 38.5% and 4.5%, respectively
(Artunduaga et al., 2009); 2) reported familial cases with autosomal recessive or dominant
modes of inheritance with variable expression and incomplete penetrance (Balci, 1974;
Balci et al., 2001; Gupta and Patton, 1995; Klockars et al., 2007; Strisciuglio et al., 1986); 3)
population-based estimates of familial cases ranging from 3 to 34% (Castilla and Orioli,
1986; Llano-Rivas et al., 1999; Mastroiacovo et al., 1995; Okajima et al., 1996); 4) more
than 18 different microtia-associated syndromes for which single-gene defects or
chromosomal aberrations have been reported; and 5) mouse models demonstrating that
specific genes are necessary for mouse ear development and that, when mutated, result in
anotia or microtia. However, only few studies have focused on the possible genetic causes of
isolated microtia-anotia in humans (Lin et al., 2009; Monks et al., 2010; Zhang et al., 2009)
and no gene has been associated so far to microtia-anotia.
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The first step to better understand the epidemiology and the etiology of any birth defect is to
analyze its distribution among the various populations. There are few published studies on
microtia-anotia frequency. The birth prevalence estimates vary greatly among countries
ranging from 0.8 to 17.4 per 10,000 (Suutarla et al., 2007). Higher prevalence has been
reported, in Ecuadorians (Castilla and Orioli, 1986; González-Andrade et al., 2010);
Chileans (Nazer et al., 2006), and Finns (Suutarla et al., 2007); with a prevalence of
respectively, 17.4, 8.8, and 4.3 per 10,000 births. In the US population higher prevalence has
been observed for Hispanics, Asians, Pacific Islanders and Native Americans when
compared to non-Hispanic Whites. Prevalence has been reported from 4 to 12.0 in Native
Americans (Aase and Tegtmeier, 1977; Jaffe, 1969; Nelson and Berry, 1984), from 2.2 to
3.2 in Asians (Forrester and Merz, 2005; Harris et al., 1996; Shaw et al., 2004), 4.61 in
Pacific Islanders (Forrester and Merz, 2005) and from 1.9 to 3.4 in US individuals of
Hispanic descent (Canfield et al., 2009; Harris et al., 1996; Shaw et al., 2004; Yang et al.,
2004). We conducted a systematic review on the frequency of microtia-anotia using data of
the three existing networks of birth defects surveillance to further explore the differences in
prevalence of microtia-anotia across countries.
Material and Methods
We used the term microtia-anotia when including microtia types I to IV, as already
mentioned; microtia was used to indicate microtia types I to III, and anotia was used for type
IV.
We used data from three sources: (a) Annual Reports of the International Clearinghouse for
Birth Defects Surveillance and Research [ICBDSR] (International Clearinghouse for Birth
Defects Surveillance and Research. Annual Report 2008, 2010) and the updated database
stored at the ICBDSR Headquarter in Rome, Italy (b) Reports of the National Birth Defects
Prevention Network [NBDPN] (Population-based Birth Defects Surveillance data from
selected states, 2002–2006–2009), and (c) the website of the European Surveillance of
Congenital Anomalies [EUROCAT] (European Surveillance of Congenital Anomalies,
2010). For US or European surveillance programs that contribute with data to NBDPN or
EUROCAT and to ICBDSR concomitantly, we used the data from ICBDSR to avoid
duplication of cases. A total of ninety-two birth defects surveillance programs were
evaluated.
The specific methods used by the surveillance programs to identify, code, and report birth
defects are available from the annual reports of ICBDSR (International Clearinghouse for
Birth Defects Surveillance and Research. Annual Report 2008, 2010) and NBDPN
(Population-based Birth Defects Surveillance data from selected states, 2002–2006–2009),
and from the EUROCAT website (European Surveillance of Congenital Anomalies, 2010).
Table 1 summarizes the main characteristics of these three surveillance networks.
In general the diagnosis of microtia-anotia was confirmed by clinical examination at local
level, however validation of the diagnosis, particularly important for the distinction between
a minor ear defect and microtia grade I or between microtia grade III and microtia grade IV
(anotia) was not possible because there was no detailed description available.
Almost all the surveillance programs are population-based except for China CBDMN, Israel
IBDSP, Japan JAOG, Mexico RYVEMCE, South America ECLAMC, Spain ECEMC and
United Arab Emirates which are hospital-based. We included these hospital-based programs
assuming that because microtia-anotia is rarely diagnosed prenatally and most of participant
hospitals are not referral centers for birth defects, the cases are fairly representative of those
in the general population, and ascertainment would be relatively unbiased. In addition,
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previous reporting of higher prevalence in Ecuador (Castilla and Orioli, 1986) and the
current hypothesis of higher prevalence in US individuals of Hispanic descent made the
analysis of the data from some of these programs essential.
Livebirths (LB), stillbirths (SB), and elective terminations of pregnancy for fetal anomalies
(ETOPFA) were included in the surveillance programs where are permitted (see table 1
notes). We included the surveillance programs not reporting ETOPFA since the influence of
ETOPFA on the total proportion of cases is very limited (4%), as evaluated from
surveillance programs reporting them (data not shown, available from the original source).
We computed the prevalence per 10,000 births and 95% confidence intervals (CI) using the
Poisson distribution and calculated medians and interquartile range (IQR) to describe the
distribution of the prevalence across the surveillance programs. . Prevalence was calculated
for total cases of microtia-anotia, microtia only, and anotia only for each surveillance
program and for large geographical areas: North America, Central and South-America,
Europe (North, West, East, and South), Asia and Australia. These geographical areas were
named and defined according to the United Nations Statistic Division Classification
(http://unstats.un.org/unsd/methods/m49/m49regin.htm). We also evaluated the prevalence
of microtia-anotia by race/ethnicity using the NBDPN data, for ICBDSR and EUROCAT
these data was not available. The numerator was the total number of cases of microtia-
anotia, microtia, and anotia occurring in LB, SB, and ETOPFA, and the denominator was
the total number of births (LB + SB).
Surveillance programs vary widely in the methodology used for conducting surveillance.
The main differences are (a) population- or hospital-based, (b) active or passive
ascertainment, (c) single or a multiple sources for ascertainment, (d) register or not
ETOPFA, and (e) different periods of life covered for ascertainment (i.e.: during the
perinatal period or up to 1–7 years of age). The validity of the data cannot be solely inferred
by these characteristics because a number of other factors are related to it. However, the
methodology employed by a program may be related to ascertainment. In order to evaluate
the variation of microtia-anotia, microtia and anotia that could be due to different
surveillance methodologies among the programs, we conducted an exploratory on
surveillance methods comparing: (a): hospital-based versus population-based programs, (b)
active versus passive surveillance programs, and (c) programs reporting ETOPFA or not.
Data for the analysis comparing active versus passive surveillance programs was only
available for the NBDPN network.
We calculated prevalence ratios (PR) and 95% CI to estimate the differences in prevalence
by large areas, race/ethnicity and, surveillance methods. Results of these exploratory
analyses are presented only for microtia-anotia since we obtained similar results for microtia
only and anotia only.
Results
Microtia-anotia
The prevalence of microtia-anotia is shown in table 2 by surveillance programs ordered by
large geographical areas and by alphabetic order in each large geographical area. For the 66
surveillance programs reporting microtia-anotia, among 43,279,396 births, 8,917 cases of
microtia-anotia were diagnosed, with an overall prevalence of 2.06 per 10,000 births (CI:
2.02–2.10). The median value was 1.43 with the interquartile range between 0.79 and 2.21
and an overall range between zero (Malta, North Dakota and Rhode Island) and 7.19
(Mexico RYVEMCE).
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For the 35 surveillance programs that reported microtia-anotia and discriminated cases in
microtia and anotia, among 25,802,806 births; 3,993 cases of microtia were diagnosed with
an overall prevalence of 1.55 per 10,000 births (CI: 1.50–1.60). The median value was 0.76
with an interquartile range between 0.50 and 1.56 and an overall range between zero (Malta)
and 5.01 (South America ECLAMC). The highest rates (last decile) were observed, in order
of increasing prevalence, in Chile Maule (2.54), Utah -USA (2.62), Texas-USA (2.66), and
South America ECLAMC (5.01) programs (Figure 1).
Anotia only
For the 61 surveillance programs that reported only anotia or anotia discriminated from
microtia, among 32,893,632 births; 1,184 cases of anotia were diagnosed, with an overall
prevalence of 0.36 per 10,000 births (CI: 0.34–0.38). The median value was 0.26 with an
interquartile range between 0.11 and 0.39 and overall range between zero, in eight
surveillance programs (UK Wessex, Spain Asturias, Ireland Cork and Kerry, Ireland SE,
Malta, United Arab Emirates, Ireland Galway, France Auvergne), and 1.98 (Western
Australia). The highest rates (last decile) were found, in order of increasing prevalence, in
Paris, France (0.82); Victoria, Australia (0.83); Isle de la Reunion, France (0.91); Sweden
(0.98); Northern Netherlands (1.13); and Western Australia (1.98) (Figure 2).
Proportion of cases of microtia only
Among the surveillance programs with data for anotia and microtia (n=35), the most
frequently observed proportion of microtia was 90% or higher (n=8). This high proportion
was observed in USA-Texas, Chile Maule, China Beijing, Spain ECEMC, South America
ECLAMC, USA-Utah, Israel IBDSP, and United Arab Emirates. The four surveillance
programs with a proportion of microtia less than 40% were Hungary, Sweden, Australia
Victoria, and Western Australia (Table 2).
Variation of prevalence of microtia-anotia by large geographical areas and race/ethnicity
The evaluation of prevalence of microtia-anotia by large geographical areas (Table 3)
showed a higher prevalence in Central and South America (PR=2.58, CI 2.43–2.74), Asia
(PR=1.39, CI 1.31–1.48), Northern Europe (PR=1.13, 1.04–1.23) and a lower rate in Eastern
Europe (PR=0.49, CI 0.43–0.56), Southern Europe (PR=0.83, CI 0.76–0.90) and Western
Europe (PR=0.88, CI 0.80–0.98) as compared to North America.
The analysis by ethnicity, performed only with the NBDPN data, showed a higher
prevalence in American Indians or Alaskan Natives (PR=2.81, CI 2.03–3.88), Hispanics
(PR=2.55, CI 2.31–2.81) and Asian or Pacific Islanders (PR=1.83, CI 1.51–2.23) and a
lower prevalence among non-Hispanic Black or African (PR=0.53, CI 0.44–0.65) as
compared to non-Hispanic whites (PR= 1.13) (Table 3).
Variation of prevalence of microtia-anotia by methodological characteristics
Using all programs with data for microtia-anotia the group of eight hospital-based programs
showed a higher prevalence as compared to the 58 population-based programs (PR=1.77, CI
1.70–1.85). Among the 8 hospital-based programs there were 3 programs from Central and
South America. The comparison of programs which reported ETOPFA with those that did
not, showed a lower prevalence in the programs not reporting ETOPFA (PR=0.95, CI 0.90–
0.99). In the NBDPN, there was a lower prevalence of microtia-anotia in the surveillance
programs with passive ascertainment (PR=0.38, CI 0.35–0.41) (Table 4).
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In this study, we conducted a systematic review of the data on the prevalence of microtia-
anotia. The data used, although published in the annual reports of the surveillance networks,
had not been previously critically analyzed or discussed in the context of the scientific
literature on microtia-anotia. Equally important, this study highlights the variation in
reporting and classification and the challenges this poses for surveillance and etiologic
studies.
This study provides a global assessment of prevalence of microtia-anotia, as observed in 92
surveillance programs in Europe, the Americas, in addition to United Arab Emirates, China,
Japan, and Australia. The findings add considerably to the available literature on microtia-
anotia. For example, compared to recent studies of microtia-anotia (Canfield et al., 2009;
Forrester and Merz, 2005; Harris et al., 1996; Mastroiacovo et al., 1995; Shaw et al., 2004;
Suutarla et al., 2007) in which data from different birth defects programs were analyzed, this
report examines more than 8,000 cases and adds further years to the assessment of rates
from surveillance programs with published data.
For most surveillance programs here analyzed the prevalence was similar to reports from
earlier population-based studies conducted in Italy, France, Sweden, Finland and United
States (Canfield et al., 2009; Forrester and Merz, 2005; Harris et al., 1996; Shaw et al.,
2004; Suutarla et al., 2007), where prevalence rates ranged between 0.83 and 4.34 per
10,000 births (Table 5). There was marked variation in the prevalence of microtia-anotia
across surveillance programs, from zero to 7.19 and with the interquartile range between
0.79 and 2.21, with a similar magnitude in variation observed for microtia and anotia when
they were analyzed separately. Heterogeneous rates were observed even within countries
where there was more than one surveillance program, such as in Italy, US, France and
Australia. This variation may have been due to registry methodological artifacts, i.e.,
differences among the surveillance programs relating to their inclusion criteria and/or their
case definition and ascertainment. Our analysis showed a higher prevalence in hospital-
based and in active ascertainment surveillance programs, this most probably account for a
proportion of the differences in prevalence. Although it is important to note that three, out of
the eight, hospital-based programs are in South and Central America, and the Hispanic
population has apparently a higher prevalence of microtia. In addition, microtia-anotia is an
external anomaly, easily recognized on physical examination after delivery; however, the
less severe form of microtia (i.e. type I according to Marx classification) is difficult to define
and the term may be used with considerable variability in clinical settings and in medical
records. This could lead to under or over reporting of microtia-anotia resulting in a false
exaggeration of the geographical variation in prevalence. Although we would expect that
anotia is unambiguous, as it is clearly defined as “absence of the ear”, it may also be used
incorrectly and explain the wide range in prevalence also observed in anotia.
Our findings also suggest that, with few exceptions, the rates of microtia seem to be higher
in the Americas and Asia when compared to Europe. And, within the Americas, we
observed an increasing trend towards regions where the proportion of Native American
ancestry is higher like Texas and Mexico, compared to Atlanta and Cuba, where the
proportion of Native American ancestry is reported to be lower. In the NBDPN data, there
was a higher prevalence among Native Americans, Hispanics, and Asians or Pacific
Islanders. These results expand on the previous studies in California, Texas, and Hawaii that
had previously demonstrated a significantly greater risk for microtia-anotia among the
Hispanic and Asian population compared with non-Hispanic African American and
Caucasian populations. (Forrester and Merz, 2005; Harris et al., 1996; Husain et al., 2008;
Shaw et al., 2004). Based on these observations, we cannot exclude the possibility that some
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attribute of Hispanics and Asians, either environmental or genetic factors, could explain
some of the variability found besides the methodological differences among the surveillance
programs.
“Hispanic” is a term used in the United States for people with origins in Spanish–speaking
countries from Central and South America living in the US. This term suffers from some
flaws such as conveying that there is a high uniformity into this group, i.e., combining
Cubans, Mexicans, Peruvians, and Argentineans, among others, in the ethnic Hispanic
group. It is well established that the various Hispanic American communities have varying
degrees of admixture of three different ancestral roots: Native American, African and
European as a consequence of, among other things, the size and number of migratory waves
to specific regions and the native population density in the areas being occupied. Some
regions had high initial native population density (e.g., Mexico, Central America and the
central Andes) while others received large waves of immigration from Europe and Asia very
recently (e.g., parts of southern South America). Studies that analyzed genetic ancestry
informative markers in individuals who self identified themselves as Hispanics have
confirmed that this group represents a continuous along the Europeans and Indigenous
Americans axes, and that the term “Hispanic” shows little correspondence with genetic
ancestry or even ancestral admixture since not all Hispanics exhibit substantial Native
American ancestry (Halder et al., 2008).
Reports of higher prevalence of microtia-anotia in Navajos (Aase and Tegtmeier, 1977;
Jaffe, 1969), the second largest Native American tribe of Northern America and the fact that
Mexicans, largest percentage of persons of Hispanic descent in the US, have a high
proportion of Native ancestry in their population could indicate that Native ancestry may be
confounding the association of Hispanic ethnicity and prevalence of microtia-anotia reported
in US studies. Furthermore, anthropological, archaeological, linguistic, and molecular data
have demonstrated that the peopling of the American continent took place by migrations
originating in northeast Asia and entering America via Beringia, giving rise to Alaskan
Natives and Amerindians among other populations in the Americas(Jobling et al., 2004). In
summary, we are compelled to speculate that the Native American shared gene pool may
play a role in the occurrence of microtia-anotia making plausible to consider a role of
ethnicity in microtia-anotia; this will be further pursued using ancestry informative markers.
The analysis of microtia and anotia separately, into two clinical subgroups, showed that in
most of the surveillance programs, from the total cases of microtia-anotia, above 80% were
cases of microtia. This finding is consistent with other studies’ findings where anotia occurs
less commonly than microtia, although most studies have observed lower proportions of
anotia cases than we did ranging between 2–14% (Canfield et al., 2009; Forrester and Merz,
2005; Harris et al., 1996; Shaw et al., 2004; Suutarla et al., 2007). In Italy and Central-east
France, previous studies showed a higher proportion of anotia cases, 22% and 44%,
respectively (Harris et al., 1996; Mastroiacovo et al., 1995). In our data set, the prevalence
of anotia was unexpectedly much higher than the prevalence of microtia in some
surveillance programs; this could be due to underreporting of microtia, a less severe type of
birth defect than anotia, or that the term “anotia” is more frequently used by some
surveillance programs. Another possibility is a truly high prevalence of anotia in those areas.
The findings of this study should be interpreted cautiously. There were some limitations in
case classification, as we were not able to distinguish between isolated, multiple malformed,
and syndromic cases. Nevertheless, in a preliminary analysis of the database from
ECLAMC, using data from 1982 to 2008, and analyzing only isolated cases, the trend in
prevalence remained the same across the countries (Luquetti et al., 2010). A second
limitation is that further splitting may have been desirable (e.g., into types I through IV,
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presence or absence of canal atresia) because of likely differences in etiology and
developmental mechanisms. Aggregating such groups (for example, types I to III under
“microtia”) in the analysis may have limited the ability to identify difference in prevalence
rates that may occur in one of such subgroups. However, limitation in phenotypic details
from most surveillance programs made such further splitting not feasible.
A second potential limitation pertains to variable ascertainment among surveillance
programs and the associated variations in prevalence rates of congenital anomalies.
Programs with active ascertainment presented higher prevalence; which was not surprising
as this methodological characteristic is usually related to better validity of data. Lastly, some
surveillance program do not report ETOPFA; however we believe that this had minimal
impact on the results because the frequency of this birth defect in ETOPFA in the other
surveillance programs was very low, accounting for only 4% of the cases. In addition, the
comparison between the programs that report ETOPFA and those which do not did not show
any significant difference in the prevalence.
On the other hand, there were several strengths to this study. It drew cases from an
unprecedented number of live and still births (> 50 million). An additional strength relates to
the fact that this is the first descriptive study about microtia-anotia conducted in a global
scale. Previous studies reporting higher risk in “Hispanics”, used data on immigrants in the
US or US individuals of Hispanic descent from Texas and California, looking at the
prevalence of microtia among smaller racial/ethnic groups, i.e. there was a small size and
representativeness of the sample. In this study we extended the analysis to surveillance
programs based on Spanish speaking countries, like Spain, Costa Rica, Cuba and most
countries of South America. We observed a marked difference within these countries that
may challenge the current concept of higher risk in the US census broad category defined as
“Hispanic”.
As we already mentioned, the prevalence could not be analyzed by type of microtia, because
currently few surveillance programs have coding systems that specifies different types of
microtia-anotia. Most birth defects surveillance programs, including those from ICBDSR
network, handle their congenital anomaly type data coded by either ICD-9 or ICD-10, with
or without British Pediatric Association extension. Some surveillance programs classify
anotia and microtia in a single code. Both the four-digit ICD-9 classification and the
alphanumeric ICD-10 have no information on severity or side(s) affected. Both revisions of
ICD have one code for microtia (744.2 and Q17.2) and one code for anotia (744.0 and
Q16.0). The British Pediatric Association modified this system to a five-digit code (744.01
for anotia and 744.21 for microtia), however, for microtia-anotia the fifth digit does not
provide additional phenotypic refinement. In summary, the ICD coding system is not
sufficiently specific in its codes for microtia-anotia. Therefore, the study of sub-phenotypes
of microtia and anotia is currently only possible in the material reported from the few
surveillance programs with verbatim description and photographic documentation of the
reported cases.
The difficulties in further characterization of the heterogeneity of the different sub-
phenotypes of microtia-anotia emphasizes the continuing need to strengthen coding training
efforts, and, more important, to improve the classification of microtia-anotia to include
severity and laterality information. The ICD classification has proven insufficient for the
classification of microtia-anotia, as for most birth defects. Therefore, the creation of new
codes, or the expansion of codes by adding new digits that would differentiate microtia types
I to IV, seems urgent. In order to generate etiological hypotheses research from data from
surveillance programs, good phenotypic information must be available. The potential for
research, which could lead to primary prevention strategies, based on birth defects
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surveillance programs require and justify modifications in the ICD. For instance, if the
assumption that the different degrees of severity of microtia-anotia represent the same risk
factors with different levels of exposure, then studies based on surveillance data or case-
control data can test that hypothesis.
Using data from the three birth defects surveillance networks, this study found that there is
heterogeneity of the prevalence of microtia-anotia in different areas of the world that is not
easily explained by surveillance methodologies differences among surveillance programs.
Great care must be taken when comparing prevalence across surveillance programs because
differences in ascertainment may be the major source of the variation in rates. However, the
magnitude of the difference in the prevalence may indicate that there may be genuine
differences in rates in these countries and that the reasons for such variations should,
therefore, be further explored. There is a clear need of prospective studies with better
phenotype ascertainment, with a case by case analysis to understand better the source of this
variability. Additionally we strongly suggest modifications in ICD classification to achieve
better phenotypic classification of microtia-anotia.
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